DT-EQUIPMENT
8.2.2021 08:58:14 CET | Business Wire | Press release
The Board of DT Equipment ehf. (DTE) (www.dtequipment.com ), a leader in real-time intelligence from liquid metals and developer of next-generation analytics for metals production and processing, is pleased to announce the appointment of Karl Matthiasson as Chief Executive Officer.
Karl Matthiasson, formerly Chairman and Chief Operating Officer, and a co-founder of DTE with extensive experience within the aluminium industry, succeeds Sveinn Gudmundsson, the Company’s founding CEO, who steps into the role of Chief Technology Officer. The changes reflect further strengthening and specialization of DTE’s executive team in line with the Company’s growing commercial strengths and market-facing focus.
Sveinn Gudmundsson, in his new role as CTO, will focus on leading the technical development and ramping up production of the Company’s analytic hardware and software systems, including further product development of associated spectrometry, optics, laser technologies, software development and artificial intelligence-based processing.
Richard MacKellar, Managing Partner at Chrysalix Ventures and Chairman of the Board of DTE, commented, “Chrysalix is excited and supportive of the organizational changes at DTE. We welcome Karl to this new role in the Company as we continue to drive the growth of DTE to fulfill its potential in leading change in the metals analytics field. I would also like to thank and acknowledge Sveinn for his outstanding leadership up to this point, which continues with the challenge of leading DTE’s technology development – the breakthrough innovations achieved were key factors for Chrysalix to invest in DTE.”
Karl Matthiasson, CEO commented, “Sveinn has been the leading force behind DTE’s success thanks to his capability to innovate and deep insight into the needs of metals producers. We thank him for his continued dedication and service to the Company -- together we will continue taking DTE’s technology to the next level.”
Find out more about DTE’s real-time liquid metals intelligence solutions at www.dtequipment.com
About DT Equipment
DTE, based in Reykjavik, Iceland, is a leading innovator in the field of real-time intelligence from liquid metals, helping customers to maximize value, efficiency, safety and sustainability. DTE’s vision is to transform metals production and processing with next-generation sensors and analytics, driving digital transformation of the metals industry towards Industry 4.0, while contributing to the 1.5-degree challenge.
DTE’s solution range combines first-in-industry LP-LIBS™ (Liquid-Phase Laser-Induced Breakdown Spectroscopy) elemental analysis with a powerful machine learning cloud platform, delivering valuable intelligence and predictive insights from liquid metals across the entire value chain.
For more information, please visit www.dtequipment.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210207005056/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom